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PERSPECTIVE
Progesterone for the treatment of 
central nervous system disorders: 
the many signaling roads for a single 
molecule
Central nervous system (CNS) injuries and neurodegenerative diseases show 
a broad spectrum of common pathophysiological processes, including oxida-
tive stress, neuroinflammation, excitotoxicity, demyelination and neurotrans-
mission dysfunctions. Over the past decades, valuable experimental investi-
gations have helped to clarify the role and timing of these multiple molecular 
and cellular mechanisms in each of these particular disorders, which usually 
overlap and critically contribute to long-term disability. However, up to now, 
no definite cures or effective disease-modifying therapies are available for any 
of these conditions. This has led to an active search of novel therapeutic ap-
proaches, including the repositioning of existing drugs for new indications, as 
a valid approach to promptly move candidate molecules to clinical trials. 
Progesterone, a steroid with a crucial role in the reproductive function in 
mammals, stands as one of these promising repositioning molecules to mod-
ulate the complex array of cellular and molecular events observed in several 
of these central nervous system diseases (Stein and Sayeed, 2019). Indeed, a 
great number of preclinical studies have provided solid basis for supporting a 
protective effect of progesterone in stroke, traumatic brain injury, spinal cord 
trauma, central and peripheral neuropathies, multiple sclerosis, and Alzhei-
mer’s and Parkinson’s disease (González et al., 2019, 2020).
Notwithstanding this remarkable number of studies exploring the beneficial 
effects of progesterone in CNS disorders, few of them offer a deeper look at the 
different receptors and complex signaling cascades involved. This perspective 
aims at expanding our view on the variety of receptors and signaling path-
ways that might be involved in progesterone-mediated actions in the nervous 
system as part of a rational strategy to promote a successful translation of ste-
roid-based therapies for the treatment of neurological diseases.
Unveiling the variety of receptors engaged by progesterone: Progesterone, 
acting as a neurosteroid/neuroactive steroid, exhibits a significant amount of 
neuroprotective, anti-inflammatory and pro-myelinating actions in experi-
mental models neurodegeneration and/or nervous system injuries (González 
et al., 2019, 2020). The central nervous system presents a wide diversity of 
progesterone receptors in both neurons and glial cells, including the “classical” 
nuclear receptor (PR). Acting as a ligand-activated transcription factor, PR 
binds to steroid-response elements within the promoter region of target genes 
regulating their expression. PR-A and PR-B, the two major PR isoforms, are 
transcribed from two distinct promoter regions of a single gene and exhibit 
distinct transcriptional activity, PR-B being a stronger transcriptional acti-
vator than PR-A. Further, extranuclear PR activation may trigger Src/Ras/
MAPK and or PI3K/Akt pathways, eventually modulating the transcription of 
genes even in the absence of progesterone-response elements. 
By using PR knockout mice (PRKO)-lacking both PR-A and PR-B iso-
forms- our laboratory and others have shed light on the crucial role of this 
“classical” receptor in mediating the beneficial actions of progesterone in the 
nervous system. In fact, PR seems to be the main mediator of the remyelin-
ating effects of progesterone, since the enhancement in the expression of the 
myelin basic protein induced by the steroid in organotypic cerebellar slices is 
lost in PRKO mice (Ghoumari et al., 2003). In addition, the lack of PR also 
impeded the increase in the density of oligodendrocyte precursor cells and the 
prevention of the apoptotic death of these cells in the injured spinal cord of 
these mice after progesterone administration, in clear contrast to the observed 
actions of the steroid in wild-type littermates (Labombarda et al., 2015).
Progesterone also requires a functional PR receptor for displaying several 
of its neuroprotective actions (Gonzalez et al., 2020). Indeed, progesterone 
was unable to prevent the loss of motoneuron and cell death in organotypic 
slices of the spinal cord from PRKO mice subjected to contusion injury. More 
recently, the expression of PR has been shown to be necessary for reducing 
brain damage and motor impairment after stroke (Zhu et al., 2019) and for 
the induction of brain-derived neurotrophic factor, a potential mediator of 
the neuroprotective effects of progesterone (Jodhka et al., 2009). 
Further, the role of PR in neuroinflammatory conditions was also proven 
in PRKO mice subjected to spinal cord injury, in which progesterone ad-
ministration did not decrease reactive gliosis and failed to reduce the inju-
ry-induced expression of pro-inflammatory cytokines (Labombarda et al., 
2015). Although PR has been detected in culture glial cells, including oligo-
dendrocytes and astrocytes, its expression has not been found in surveillance 
microglial cells. Certainly, much remains to be explored regarding the role of 
PR in the modulation of glial responses, in particular during in vivo neuroin-
flammatory challenges and demyelinating disorders.
Less information is available on the role of PR isoforms expression after 
nervous system injury or during disease. Since both isoforms show distinct 
transcriptional properties, any disruption of their balanced expression may 
impact on the regulation of particular and/or common arrays of target genes. 
Interestingly, the unequal expression of these two isoforms between the brain 
and retina after traumatic brain injury might account for the differential 
anti-inflammatory actions of progesterone within these tissues (Allen et al., 
2016). To add complexity, the regulation of the expression of PR A/B isoforms 
may not only depend on DNA methylation and the chromatin basal state 
of their respective promoters but also on the participation small non-cod-
ing RNAs termed microRNAs (miRNAs) that mediate gene silencing at the 
post-transcriptional level.
Another exciting perspective has been opened after the identification of a 
set of novel proteins, including synaptic proteins and regulators of metabo-
lism, that form complexes with PR in a ligand- and isoform-specific manner. 
Through the use of combined mass spectrometry and reverse phase protein 
arrays, Acharya et al. (2017) provided clear evidences that several female 
mouse hypothalamic proteins form complexes with PR-A, PR-B, or both in a 
ligand-dependent manner, including synapsin-I and synapsin-II, suggesting 
that both isoforms function in synaptic plasticity (Acharya et al., 2017). In 
support of this notion, progesterone increased synaptic density in primary 
cortical neurons, suggesting a function for progesterone in synapse formation 
in cortical neurons. Further, differential interactions of signaling molecules 
with PR may be important for isoform-specific rapid effects of PR in brain. 
Indeed, they also found that MAPK1 kinase associated with PR-B, but not 
PR-A, and detected hormone-dependent interactions between Src kinase with 
PR-A, but not PR-B. Moreover, both PR isoforms were associated with a key 
regulator of energy homeostasis, FoxO1, pointing to a novel role for PR in 
energy metabolism. These relevant data open up new challenges to unravel in 
the context of CNS disorders.
Although most studies have mainly focused their attention on the genomic 
actions of the well-characterized “classical” PR (Gonzalez et al., 2020), addi-
tional receptors and different intracellular targets may explain the multiple 
actions of progesterone. Indeed, membrane progesterone receptors (mPRs) 
and membrane progesterone binding protein (PGRMC1) have been also de-
scribed in the CNS. Without being related to nuclear steroid receptors, mPRs 
and PGRMC1 and 2 can set up fast cell-surface actions in the nervous system, 
appearing as potential players to be considered when designing steroid-based 
therapies.
The membrane-bound mPRs are associated with G protein that, depending 
on the receptor subtype involved, activate intracellular pathways that may 
lead to increase or decrease AMPc levels. The expression of mPR receptor 
subtypes in specific cellular and CNS locations validate their role in mediating 
the protective actions of progesterone during inflammation and altered ion 
and water homeostasis in the injured CNS. However, the cellular distribution 
and the concrete function of different mPR isoforms in progesterone signaling 
in health and disease have not been fully depicted and clearly deserve further 
research. 
Far from being clarify, PGRMC1 intracellular signaling pathways and func-
tions remain intriguing. PGMR1 has been described as an adaptor protein for 
mPRs (Thomas et al., 2014) facilitating mPR signaling and as alternative part-
ner to mediate progesterone actions on mitochondria (Gonzalez et al., 2020). 
More recently, Wu et al. (2019) also found that progesterone significantly 
improves glucose metabolism both in cellular and transgenic models of Alz-
heimer’s disease, through a mechanism involving the activation of PGRMC1, 
offering a new target to explore during the administration of this steroid in 
pathological conditions.
Notably, progesterone and several of its related metabolites are modulators 
of certain neurotransmitter systems and channels, such as γ-aminobutyric 
acid (GABA) and N-methyl-D-aspartate receptors, transient receptor potential 
(TRP) channels and sigma-1 receptor (Sigma-1R), adding intricacy to steroids 
actions in the nervous system. In line with this notion, a recent report (Mo-
rales-Lazaro et al., 2019), provided valuable insights regarding the molecular 
interplay between the Sigma-1R, steroids, and ion channels, shedding light on 
novel aspects of progesterone in pain modulation. The Sigma-1R is a protein 
mainly localized to the endoplasmic reticulum where it functions as a chaper-
one and binds progesterone, a major endogenous antagonist of this receptor. 
Interestingly, Sigma-1R and TRP vanilloid channels (TRPV1), with pivotal 
roles in painful signal transduction, are associated in the endoplasmic reticu-
lum, improving TRPV1 stability and resulting in suitable TRPV1 expression 
in the plasma membrane, where the channel transmits noxious signals. To be 
noted, they found that antagonism of Sigma-1R by progesterone results in the 
down-regulation of TRPV1 expression in the plasma membrane of sensory 
neurons and, consequently, a decrease in nociceptive responses to harmful 
stimulation. This observations were achieved both in male rats treated with a 
synthetic antagonist of Sigma-1R and in pregnant rats, which display high lev-
els of circulating progesterone and exhibited attenuated pain-induced behavior 
through the disruption of the Sigma-1R/TRPV1 complex. Therefore, elevated 
levels of progesterone, such as those found during pregnancy, could confer 
protection against painful situations and open new roads to explore possible 
progesterone interactions with Sigma-1R in pathological pain conditions.
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Progesterone may also exert important effects involving its conversion 
to allopregnanolone that does not bind PR and acts through non-classical 
pathways. For instance, the anesthetic and antiseizure activity of progesterone 
mainly occurs through its conversion to the neurosteroid allopregnanolone, 
a potent endogenous positive modulator of the GABAA receptor complex, 
the principal mediator of the fast inhibitory transmission within the CNS. 
However, allopregnanolone binding is not limited to GABAA receptors but 
also can bind to mPRs and to pregnane X receptor that might mediate sev-
eral of the neuroprotective effects of this steroid. In line with these beneficial 
roles of allopregnanolone, Mensah-Nyagan et al. developed a series of novel 
synthetic analogs of allopregnanolone, as part of a crucial process to enhance 
the efficacy of steroid-based therapies (for a review, Gonzalez et al., 2019). 
In vitro testing has revealed that these compounds, acting as mitochondrial 
neuromodulators and neuroprotective drugs, show notable advantages over 
the original molecule to counteract mitochondrial bioenergetic deficits and 
improve neuronal cell survival under oxidative stress, widening the options to 
be translated from the laboratory to the bedside.
Conclusions and future directions: Based upon an active research over the 
past decades, it is now clear that targeting a unique mechanism or signaling 
pathway to overcome the complex network of processes that take place during 
CNS trauma or neurodegenerative disease represents an inadequate approach. 
This has led to the search of novel strategies such as repositioning of drugs 
with several mechanisms of action, as is the case of progesterone. It is now 
clear that an array of receptors, including neurotransmitter receptors, may be 
acting in an integrated and complex fashion to promote the neuroprotective 
progesterone-dependent actions in the nervous system (Figure 1).
However, and despite the wealth of experimental evidence supporting 
the beneficial effects of progesterone, this steroid, like many drugs that were 
successful in pre-clinical trials, did not work as expected in clinical trials. 
Certainly, many lessons have been learnt from clinical trials that forced to 
revise many aspects of their design. Moreover, refining our knowledge on 
progesterone’s mechanisms of action for the different pathological should be 
mandatory to provide solid support for translational success.
Indeed, novel aspects of progesterone signaling are emerging that introduce 
unexpected factors to take into account when designing progesterone-based 
therapies. This complex scenario includes the interaction of PR with synaptic 
proteins, the bioconversion of progesterone to reduced metabolites, and the 
differential expression of mPRs, PGRMC1 and PR isoforms in each patho-
logical condition. All these challenges release the way to novel research in the 
field and open future perspectives on how to fill the gap between human and 
animal studies to develop effective steroid-based therapies for the treatment 
of CNS trauma, neuropathic pain and neurodegenerative diseases.
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Figure 1 Multiple receptors and signaling 
partners are involved in progesterone and 
allopregnanolone actions in central nervous 
system. 
Progesterone can bind to an array of progesterone 
receptors including the classic nuclear receptor (PR), 
progesterone membrane receptors (mPR) and the 
membrane-associated protein progesterone recep-
tor-membrane component 1 (PGRMC1). A balance 
between PR-A and PR-B isoforms may influence 
progesterone effects. In addition, small-non coding 
RNAs (miRNAs) control the level of PR expression 
and in turn operate as mediators of progesterone 
signaling. The functions of mitochondrial PR and 
PGRMC1 remain to be explored. Progesterone also 
acts as a competitive antagonist of Sigma 1R asso-
ciated to the endoplasmic reticulum. Finally, the 
conversion to allopregnanolone, that does not bind 
to PR but may act as a potent positive allosteric 
modulator of γ-aminobutyric acid (GABA)A recep-
tor, extends the variety of progesterone-associated 
mechanisms. DHP: Dihexadecyl phosphate; ER: 
endoplasmic reticulum.
